Ohio Dentist Loses DEA Registration After State Authority Disappears
Published Date: 10/26/2026
Notice
Summary
Dr. Barry Backiewicz from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the decision to revoke his registration is final. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA revokes registration when state license lost
The DEA may revoke a medical practitioner's federal controlled-substances registration when the practitioner no longer has state authority to prescribe or handle controlled drugs. The Order cites 21 U.S.C. 824(a)(3) and 21 U.S.C. 823(g)(1) and applies the rule that loss, suspension, or expiration of a state license makes a practitioner ineligible to keep a DEA registration.
Dr. Backiewicz's DEA registration revoked; renewals denied
DEA Certificate of Registration No. BB2606436 issued to Barry Backiewicz, D.D.S., is revoked and the Agency denies any pending renewal, modification, or additional registration applications in Ohio. The Order finds his Ohio dental license expired on December 31, 2023, notes his DEA registration expired July 31, 2026, and states the revocation is effective November 25, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-21799, Vida Janson, M.D.; Decision and Order
Vida Janson, M.D., lost her license to handle controlled substances in Washington State, so the DEA has officially revoked her registration to prescribe or dispense these drugs. This means she can no longer legally work with controlled substances, effective immediately. If you’re a healthcare provider or patient in Washington, this change ensures only authorized professionals handle these medications.
2026-21413, Jefferson Burroughs, M.D.; Decision and Order
Dr. Jefferson Burroughs from Ohio lost his DEA registration to handle controlled substances because he no longer has the legal authority to prescribe them in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of July 31, 2026. This means Dr. Burroughs can’t legally prescribe or manage controlled drugs anymore, affecting his medical practice and patients.
Previous / Next Documents
Previous: 2026-21724, Notice of Intent To Renew a Previously Approved Information Collection
The National Institute of Food and Agriculture (NIFA) plans to renew its info collection for the Children, Youth, and Families at Risk (CYFAR) Year End Report for three more years. This affects community programs that support kids and families, helping NIFA track progress and improve services. Comments on this plan are open until December 28, 2026, with no new costs involved.
Next: 2026-21726, Agency Information Collection Activities; 30 CFR 822-Special Permanent Program Performance Standards-Operations in Alluvial Valley Floors
The Office of Surface Mining wants to keep collecting info to make sure mining near alluvial valley floors stays safe and follows the rules. This affects mining companies who must keep protecting these special areas. They’re asking for public comments by November 25, 2026, and there’s no new cost or big changes—just a renewal to keep things running smoothly.